Newron’s Add-On Treatment Shows Promise In Newly Popular Schizophrenia Field
Italian Firm Needs A Partner For Final Phase III
Newron’s evenamide worked in a Phase II/III trial as an add-on to antipsychotic drugs in patients with inadequate response to monotherapy at a time when schizophrenia has piqued the interest of big pharma.
